Ideal cardiovascular health and liver enzyme levels in European adolescents; the HELENA study

Imagem de Miniatura
Arquivos
art_LABAYEN_Ideal_cardiovascular_health_and_liver_enzyme_levels_in_2017.PDF (459.41 KB)
Citações na Scopus
11
Tipo de produção
article
Data de publicação
2017
Editora
SPRINGER
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
LABAYEN, Idoia
RUIZ, Jonatan R.
HUYBRECHTS, Inge
ORTEGA, Francisco B.
CASTILLO, Manuel
SJOSTROM, Michael
GONZALEZ-GROSS, Marcela
MANIOS, Yannis
WIDHALM, Kurt
KAFATOS, Anthony
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF PHYSIOLOGY AND BIOCHEMISTRY, v.73, n.2, p.225-234, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
There is an increasing interest for the role of liver enzymes as predictors of non-liver-related morbidity and mortality. The American Heart Association (AHA) described the ideal cardiovascular health concept as a score of seven cardiovascular health behaviors and factors that can be used to monitor and predict ideal cardiovascular health over time. This study aimed to examine the association of the ideal cardiovascular health (ICH), as defined by the AHA, with liver enzyme levels in European adolescents. A total of 637 adolescents (54.6% females), aged 14.6 +/- 1.2 years from nine European countries participated in this cross-sectional study. Blood levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase were measured and the AST/ALT ratio calculated. Ideal cardiovascular health was defined as meeting ideal levels of the following components: four behaviors (smoking, body mass index, physical activity, and diet) and three factors (total cholesterol, blood pressure, and glucose). A higher number of ideal cardiovascular health behaviors, factors, and ideal cardiovascular health index were associated with lower ALT (P < 0.05, P < 0.001, and P < 0.001, respectively) and gamma-glutamyltransferase (P < 0.001, P < 0.01, and P < 0.001, respectively) levels. Similarly, a higher number of ideal cardiovascular health behaviors (P < 0.01), factors (P < 0.01), and ideal cardiovascular health index (P < 0.001) were associated with a higher aspartate aminotransferase to alanine aminotransferase ratio. These findings reinforce the usefulness of the ICH index as an instrument to identify target individuals and promote cardiovascular health in adolescents, and it also extends these observations to the liver manifestation of the metabolic syndrome.
Palavras-chave
Ideal cardiovascular health (ICH), Liver enzymes, Adolescents
URI
https://observatorio.fm.usp.br/handle/OPI/20196
Referências
  1. Aatola H, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000532
  2. Alkerwi A, 2014, BR J NUTR, V5, P1
  3. Alman AC, 2014, PEDIATR DIABETES, V15, P502, DOI 10.1111/pedi.12120
  4. Armstrong MJ, 2014, HEPATOLOGY, V59, P1174, DOI 10.1002/hep.26717
  5. Breitling LP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013116
  6. Burgert TS, 2006, J CLIN ENDOCR METAB, V91, P4287, DOI 10.1210/jc.2006-1010
  7. Cole TJ, 2012, PEDIATR OBES, V7, P284, DOI [10.1111/j.2047-6310.2012.00064.x, 10.1111/j.2047-6310.2012.000064.x]
  8. Danielsson J, 2014, WORLD J GASTROENTERO, V20, P11743, DOI 10.3748/wjg.v20.i33.11743
  9. Georgoulis M, 2015, J HUM NUTR DIET, V28, P409, DOI 10.1111/jhn.12323
  10. Gonzalez-Gross M, 2008, INT J OBESITY, V32, pS66, DOI 10.1038/ijo.2008.185
  11. Hallsworth Kate, 2015, Frontline Gastroenterol, V6, P44
  12. Higashikawa A, 2005, ARCH MED RES, V36, P567, DOI 10.1016/j.arcmed.2005.03.027
  13. Kelishadi R, 2009, ATHEROSCLEROSIS, V204, P538, DOI 10.1016/j.atherosclerosis.2008.09.034
  14. Kong APS, 2013, PEDIATR OBES, V8, P351, DOI 10.1111/j.2047-6310.2012.00115.x
  15. Kontogianni MD, 2014, CLIN NUTR, V33, P678, DOI 10.1016/j.clnu.2013.08.014
  16. Kotronen A, 2008, DIABETOLOGIA, V51, P130, DOI 10.1007/s00125-007-0867-x
  17. Kotronen A, 2008, GASTROENTEROLOGY, V135, P122, DOI 10.1053/j.gastro.2008.03.021
  18. Kozakova M, 2012, HEPATOLOGY, V55, P1406, DOI 10.1002/hep.25555
  19. Labayen I, 2015, PEDIATR OBES, V10, P361, DOI 10.1111/ijpo.273
  20. Labayen I, 2014, CLIN NUTR, V33, P859, DOI 10.1016/j.clnu.2013.10.008
  21. Laitinen TT, 2012, CIRCULATION, V125, P1971, DOI 10.1161/CIRCULATIONAHA.111.073585
  22. Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703
  23. Minihane AM, 2015, BRIT J NUTR, V114, P999, DOI 10.1017/S0007114515002093
  24. Mohammadi F, 2014, J PEDIATR GASTR NUTR, V58, P463, DOI 10.1097/MPG.0000000000000246
  25. Moreno LA, 2008, INT J OBESITY, V32, pS4, DOI 10.1038/ijo.2008.177
  26. Oikonen M, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000244
  27. Pahkala K, 2013, CIRCULATION, V127, P2088, DOI 10.1161/CIRCULATIONAHA.112.000761
  28. Patel DA, 2007, METABOLISM, V56, P792, DOI 10.1016/j.metabol.2007.01.010
  29. Ruiz JR, 2007, INT J OBESITY, V31, P1545, DOI 10.1038/sj.ijo.0803693
  30. Ruiz JR, 2015, HEART, V101, P766, DOI 10.1136/heartjnl-2014-306750
  31. Ruiz JR, 2011, AM J EPIDEMIOL, V174, P173, DOI 10.1093/aje/kwr068
  32. Schneider ALC, 2013, DIABETIC MED, V30, P926, DOI 10.1111/dme.12187
  33. Schwimmer JB, 2005, PEDIATRICS, V115, pE561, DOI 10.1542/peds.2004-1832
  34. Schwimmer JB, 2008, CIRCULATION, V118, P277, DOI 10.1161/CIRCULATIONAHA.107.739920
  35. Shay CM, 2013, CIRCULATION, V127, P1369, DOI 10.1161/CIRCULATIONAHA.113.001559
  36. Sorbi D, 1999, AM J GASTROENTEROL, V94, P1018
  37. Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103
  38. Strauss RS, 2000, J PEDIATR-US, V136, P727, DOI 10.1067/mpd.2000.102940
  39. Swinburn B, 2015, LANCET, V385, P2534, DOI 10.1016/S0140-6736(14)61747-5
  40. Vereecken CA, 2008, INT J OBESITY, V32, pS26, DOI 10.1038/ijo.2008.180
  41. Waxman Amalia, 2003, Food and Nutrition Bulletin, V24, P281
  42. Wicklow BA, 2012, DIABETES CARE, V35, P905, DOI 10.2337/dc11-1754

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - ODS/03